Grove Reduces Clinical Trial Enrollment Time with AI

Streamlining Clinical Trial Enrollment with AI

Tran Le, while studying engineering at Stanford University, encountered significant difficulties when attempting to participate in a clinical trial for a chronic health issue. Identifying potential trials proved challenging, primarily due to a complex and time-consuming enrollment process.

This process involved extensive email correspondence with clinical trial sites and the completion of substantial, multi-page forms. Recognizing a clear need for improvement, Le envisioned leveraging generative AI to drastically reduce trial initiation times – from weeks to mere minutes.

The Founding of Grove AI

Last year, Le collaborated with Sohit Gatiganti, a fellow engineer from Stanford Medicine, to establish Grove AI. Their shared goal was to address the inefficiencies inherent in clinical trial enrollment.

While physician referrals are common, many individuals proactively seek suitable trials through online registries like clinicaltrials.gov. These resources facilitate the discovery of relevant studies, but connecting with trial administrators often presents obstacles.

Understaffing, bureaucratic processes, and legacy systems frequently impede progress within the healthcare sector, contributing to these delays.

Introducing Grace: An AI-Powered Enrollment Agent

Le and Gatiganti assert that Grove AI’s AI agent, named Grace, effectively resolves the enrollment bottleneck. Grace proactively contacts patients immediately upon expressing interest in a trial.

Utilizing a voice-based AI system, Grace conducts preliminary screenings to ascertain patient eligibility. Upon qualification, Grace can then schedule an initial visit to the clinical site for final assessment by trial managers.

Early Traction and Growth

Since its inception eight months ago, Grove AI reports having engaged with over 70,000 patients. This has resulted in the scheduling of 7,000 in-person appointments and the acquisition of two customers committed to multi-year contracts.

The company believes its approach is unique, stating that no other organization currently employs generative AI to accelerate patient enrollment in clinical trials. “Numerous companies in this field are reaching out to explore potential partnerships,” Le noted.

Seed Funding and Investor Confidence

Investors share this optimistic outlook, recognizing the potential value in simplifying the clinical trial enrollment process.

Grove AI recently announced a $4.9 million seed funding round, spearheaded by venture firm A*, with contributions from Afore Capital, LifeX Ventures, Upfront Ventures, and Pear VC.

Market Potential and Future Outlook

Gautam Gupta, co-founder and general partner at A*, believes the market Grove AI is targeting, while not currently massive, possesses significant growth potential.

A* estimates the total addressable market at approximately $10 billion, though it remains unclear whether Grove AI’s product encompasses the entirety of this opportunity. Gupta anticipates that advancements in AI and computational biology will fuel an expansion of drug research and clinical trials.

“Grove is well-positioned to benefit substantially from this trend,” he stated.

Beyond Simplification: Data Management and Competitive Advantage

Gupta acknowledges that the underlying technology of Grove AI is not exceptionally complex. However, the strong demand from organizations traditionally resistant to adopting new technologies excites him.

He also highlights the potential of Grove AI’s efforts to collect and organize patient data into a robust relationship management tool. Currently, most clinical sites rely on spreadsheets for tracking patient interactions.

Grove AI’s AI-driven product offers a more sophisticated solution for managing patient records. “While the value of this opportunity is difficult to quantify at present, it establishes a significant competitive advantage and will likely generate additional revenue streams over time,” Gupta concluded.

Stay informed about the latest in AI! Sign up for TechCrunch’s AI-focused newsletter, delivered weekly to your inbox.